@laurynbosstick's peptide therapy claims need context

What did @laurynbosstick actually say?

In this video, Lauryn Bosstick runs through her personal peptide regimen in casual, conversational detail. She describes using NAD (both IV and injectable), a compound she calls "epimoralin and tesmoralin" which she frames as "a synthetic HGH" that "promotes your own production of human growth hormone," and a combination she calls the "Wolverine's stack." She says the Wolverine stack contains BPC-157, TB-500, KPV, and GHK-Cu, all in a single daily injection. Her framing throughout is personal, lifestyle-oriented, and tied specifically to joint health and recovery around age 50.

A few quick terminology notes before we dig in: the compounds she likely means are ipamorelin (not "epimoralin") and tesamorelin (not "tesmoralin"). These are real, distinct peptides, and the mispronunciation matters because people searching for what she's describing may not find accurate information.

Does the science back this up?

Partially, and with important caveats. The individual peptides in the "Wolverine stack" each have legitimate research behind them, but most of that research is preclinical, meaning it was done in rodents, not humans. GHK-Cu has published human-adjacent data on skin and tissue repair (Pickart and Margolina, 2018, Biomolecules), but its systemic injectable effects in healthy adults are not well-characterized in clinical trials.

BPC-157 has a substantial body of animal research showing accelerated tendon, ligament, and gut healing. A 2021 review by Sikiric et al. in Current Pharmaceutical Design summarized the animal data favorably, but as of this writing, no large-scale human RCTs have been completed. TB-500 (Thymosin Beta-4) has some human trial data in cardiac contexts (Goldstein et al., 2012, Annals of the New York Academy of Sciences), but again, its use as a general recovery agent in healthy people is extrapolated from limited evidence. KPV is a tripeptide with anti-inflammatory data primarily from gut research in mice. Stacking all four in one injection has no published clinical trial behind it, full stop.

What did they get wrong (or right)?

She gets credit for correctly distinguishing that these compounds work by stimulating the body's own processes rather than replacing hormones directly. Her description of ipamorelin and tesamorelin as compounds that "promote your own production of human growth hormone" is basically accurate for ipamorelin, which is a GHRP (growth hormone releasing peptide). Tesamorelin is a GHRH analogue, FDA-approved for HIV-associated lipodystrophy, so calling it a generic lifestyle peptide glosses over a meaningful clinical context.

Where she goes wrong is scope. Framing this stack as something people in their 50s should consider for joints, without mentioning that these are largely unregulated compounded peptides with limited human safety data, is a real gap. The casual "it's in one shot you take every day" delivery skips over the fact that combining four peptides in one preparation raises stability, dosing, and interaction questions that no published study has answered. Mislabeling ipamorelin as "epimoralin" isn't just a slip; it can lead viewers to search for something that doesn't exist.

What should you actually know?

These peptides are not FDA-approved for the uses described here. BPC-157, TB-500, KPV, and GHK-Cu are available through compounding pharmacies in a regulatory gray zone in the United States, and the FDA has taken action against some compounders distributing them. That doesn't mean they're inherently dangerous, but it does mean quality control, purity, and dosing consistency vary significantly between suppliers.

The "Wolverine stack" framing is clever marketing language, not a clinical protocol. If you're 50 and have joint pain, there are interventions with actual human trial data behind them, including physical therapy, PRP for specific tendinopathies, and certain nutraceuticals. Peptides may eventually join that list as research matures, but the current evidence doesn't support the casual confidence in this video. Anyone considering these compounds should be working with a licensed provider who can assess contraindications, not taking cues from a TikTok stack walkthrough.

• NAD supplementation has more human data than most peptides mentioned here, though IV versus injectable bioavailability differences are still being studied.
• Tesamorelin's FDA approval is specific to a single indication. Using it off-label is a different clinical conversation entirely.